Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders for Enanta Pharmaceuticals, Inc., held on February 6, 2014. The filing details the voting outcomes for director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Class I Directors
- Bruce L. A. Carter, Ph.D.: Elected with 10,301,466 votes for, 20,261 votes withheld, and 3,510,425 broker non-votes.
- Jay R. Luly, Ph.D.: Elected with 10,184,827 votes for, 136,900 votes withheld, and 3,510,425 broker non-votes.
- Both directors will serve until the 2017 Annual Meeting.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2014.
- Votes: 13,806,526 for, 19,356 against, 6,270 abstain, and 0 broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class I directors (Bruce L. A. Carter and Jay R. Luly) through the 2017 Annual Meeting.
- Confirm the engagement of PricewaterhouseCoopers LLP for the fiscal year ending September 30, 2014.
- Note the significant number of broker non-votes (3,510,425) recorded for the director election proposals.